

Association of Naïve B Cells with Humoral Response to SARS-CoV-2 Vaccination

Eduard Schulz^{1*}, Isabel Hodl^{2*}, Patrick Forstner³, Stefan Hatzl¹, Nazanin Sareban⁴, Martina Moritz⁴, Johannes Fessler⁵, Barbara Dreo², Barbara Uhl¹, Claudia Ur⁴, Andrea Grisold³, Michael Khalil⁶, Barbara Kleinhapp³, Christian Enzinger⁶, Martin H. Stradner², Hildegard Greinix¹, Peter Schlenke⁴ and Ivo Steinmetz³

*ES and IH contributed equally to the manuscript.

¹Division of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

²Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

³Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria

⁴Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria

⁵Institute of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria

⁶Department of Neurology, Medical University of Graz, Graz, Austria

Corresponding author:

Martin H. Stradner
Division of Rheumatology and Immunology
Department of Internal Medicine
Medical University of Graz
Auenbruggerplatz 15, 8036 Graz, Austria
Tel: +43/316/385-81794
Fax: +43/316/385-17813
E-mail: martin.stradner@medunigraz.at

Key words: mRNA vaccine, COVID-19, B cells, immunodeficiency, cancer

Word count: 2906 words

Key messages

What is already known about this subject?

- ▶ Humoral vaccination response is impaired in patients with immunodeficiency or B-cell-depleting therapies, such as anti-CD20 antibody therapy or hematopoietic stem cell transplantation.
- ▶ Current recommendations advise an interval of six months between the most recent anti-CD20 antibody administration and vaccination.

What does this study add?

- ▶ Immunocompromised patients can achieve anti-spike protein antibody levels similar to those in healthy subjects after vaccination.
- ▶ Independent of concurrent immunosuppressive treatment or condition, the number of naïve B cells, but not the total number of B cells, is strongly associated with anti-spike protein antibody levels, similar to that in healthy subjects.

How might this impact on clinical practice or future developments?

- ▶ Assessment of the abundance of naïve B cells in immunocompromised patients could be used to schedule vaccinations for optimal antibody responses.

ABSTRACT

Objectives

Immunocompromised patients are at risk of severe coronavirus disease 2019 and are considered a high priority for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Humoral vaccination response is impaired in these patients when circulating B cells are lacking. We aimed to analyze B-cell subsets at the time of vaccination to identify potential predictors of humoral vaccination response.

Methods

Patients (n=120) receiving B-cell-depleting therapy (n=41), those suffering from inborn errors of immunity (n=25) and hematologic malignancies (n=56), and healthy controls (n=79) were vaccinated twice with BNT162b2 or mRNA-1273. B-cell subsets were analyzed prior to vaccination. Two independent anti-SARS-CoV-2 S immunoassays targeting the receptor-binding domain (RBD) or trimeric S protein (TSP) were performed three to four weeks after the second vaccination.

Results

Seroconversion occurred in 100% of the healthy controls, in contrast to 67% (RBD) and 82% (TSP) of the patients, while only 32% (RBD) and 22% (TSP) achieved antibody levels comparable to those of healthy controls. The number of circulating naïve B cell was strongly associated with antibody levels ($r=0.761$, $P<0.001$) across all immunosuppressive treatments or conditions. In multivariable analysis, the number of naïve B cells was an independent predictor for achieving antibody levels comparable to healthy controls, and receiver operating characteristic analysis predicted that at least six naïve B cells per μL were required.

Conclusions

Assessing the abundance of naïve B cells in immunocompromised patients could be useful in predicting the optimal vaccination response.

1 INTRODUCTION

2 Coronavirus disease 2019 (COVID-19) results in increased morbidity and mortality in
3 immunocompromised patients.[1-3] Immunodeficiency can be primary (PID) due to underlying
4 genetic causes such as common variable immunodeficiency or secondary (SID) resulting from
5 hematologic malignancies (HM), immunosuppressive therapies, or hematopoietic stem cell
6 transplantation (HSCT). In a recent study of 100 patients with COVID-19 disease, patients with PID
7 and SID demonstrated higher morbidity and mortality than the general population, while the outcomes
8 of individuals suffering from SID were the worst.[1] In patients with HM and COVID-19, a mortality
9 rate of 34% [95% confidence interval (CI): 28–39] has been reported in adults.[4]

10 Due to the high risk of severe COVID-19 in immunocompromised patients, they are considered a high
11 priority for COVID-19 vaccination.[5-9] However, trials of the currently approved COVID-19
12 vaccines have excluded individuals diagnosed with immunodeficiency or malignancy; therefore,
13 information on the efficacy and safety of the vaccines in these patients is sparse.[10-13] Hagin et al.
14 reported specific antibody responses in 18/26 (69%) patients with inborn errors of immunity and
15 spike-peptide-specific T cells in 19/26 (73%) patients two weeks after administration of the second
16 dose of BNT162b2 vaccine.[10] Braun-Moscovici et al. observed significant severe acute respiratory
17 syndrome coronavirus 2 (SARS-CoV-2) IgG antibody levels in 227/264 patients (86%) with
18 autoimmune rheumatic diseases (AIRD) 4–6 weeks after the second dose of BNT162b2 vaccine.[11]
19 Other investigators confirmed these vaccination responses in AIRD patients and reported significant
20 reductions in seropositivity rates in patients receiving B-cell-depleting therapy and
21 glucocorticoids.[12, 13] Lack of antibody responses and significantly lower antibody levels in
22 responders have been reported in HM patient cohorts in general[14-16] and in selected patients with
23 multiple myeloma, chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma.[17-21]
24 Vaccinations have a low efficacy when administered soon after HSCT and anti-CD20 therapies.[5, 22,
25 23]

26 Recently, Mrak et al. showed that a humoral response to mRNA vaccines can also be induced in
27 patients after therapy with rituximab as long as peripheral B cells are measurable.[24] However, the

28 number of circulating B cells or of a certain B-cell subset associated with a humoral vaccination
29 response comparable to healthy individuals is unknown. A marker predictive of vaccination response
30 would aid to schedule vaccinations in the immunocompromised to achieve optimal vaccination
31 response.

32 We hypothesize that specific B-cell subsets present during vaccination are associated with a humoral
33 vaccination response. Herein, we used data from an interim analysis of the prospective, open-label,
34 phase IV CoVVac trial (NCT04858607) to test the hypothesis.

35

36 **METHODS**

37 **Study design and participants**

38 We report the data of an interim analysis of the CoVVac trial (NCT04858607), which is an ongoing
39 open-label, phase IV, prospective, monocentric study at the Medical University of Graz, Austria. After
40 approval by the ethics committee of the Medical University of Graz in April 2021 (EK 1128/2021),
41 patients with inborn errors of immunity, hematological malignancies, those receiving B-cell-depleting
42 therapy, and healthy controls were recruited before receiving their first dose of COVID-19 vaccine.
43 The detailed study protocol is provided in the Supplementary Information. In brief, blood was drawn
44 before the first vaccination with BNT162b2 (BioNTech/Pfizer) or mRNA-1273 (Moderna) for
45 peripheral blood mononuclear cell (PBMC) isolation and lymphocyte phenotyping. The second
46 vaccination was administered 21 (BNT162b2) or 28 days (mRNA-1273) after the first. Blood
47 sampling was performed 21–28 days after the second vaccination to analyze the COVID-19-specific
48 antibody response as the primary endpoint.

49 **Patient and public involvement**

50 It was not appropriate or possible to involve patients or the public in the design, or conduct, or
51 reporting, or dissemination plans of our research.

52 **Lymphocyte phenotyping**

53 Blood samples from the baseline visit were processed within 4 hours for analysis by flow cytometry.
54 For lymphocyte phenotyping, ethylenediaminetetraacetic acid whole blood was stained for CD3, CD4,
55 CD8, CD45, CD16, CD56, and CD19, as previously described.[25] For B-cell phenotyping, PBMCs
56 were isolated from lithium heparin whole blood by Ficoll gradient density centrifugation. One million
57 PBMCs were incubated with the following antibodies: CD19-VioGreen, anti-IgD-VioBlue, CD24-
58 PerCP-Vio700, CD38-FITC, CD27-APC, CD86-PE-Vio770, CD21-APC-Vio770, and anti-IgM-PE
59 (Miltenyi Biotec, Bergisch Gladbach, Germany). Samples were measured using a FACSLyric flow
60 cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed using the FACSSuite (BD
61 Biosciences). The gating strategy is shown in Supplemental Figure 1.

62 **Antibody assays**

63 Serum was obtained 21–28 days after the second vaccination, aliquoted, frozen, and stored at -80°C
64 until analysis was performed in batches. Two CE-marked serological tests were performed according
65 to the manufacturers' protocols to determine and quantify specific antibodies against SARS-CoV-2. A
66 Specific IgG was determined using the Roche Elecsys anti-SARS-CoV-2 S electrochemiluminescence
67 immunoassay targeting the receptor-binding domain of the viral spike protein using a Cobas e 801
68 analytical unit (Roche Diagnostics GmbH, Mannheim, Germany).[20, 24] Its quantification range lies
69 between 0.4 and 2500 U/mL, with a cut-off of 0.8 U/mL for positivity. Specific IgG was measured by
70 Liaison SARS-CoV-2 TrimericS IgG test on Liaison XL (DiaSorin, Saluggia, Italy), which is a
71 chemiluminescence immunoassay quantifying antibodies that target the trimeric S protein.[21] Results
72 are provided in binding antibody units (BAU) with a quantification range of 4.81–2080 BAU/mL.
73 Values ≥ 33.8 BAU/mL were considered positive.

74 **Statistical analysis**

75 All statistical analyses were performed using Stata 16.1 (Stata Corp., Houston, TX, USA). Continuous
76 data were reported as medians (25th–75th percentile) and categorical data as absolute frequencies (%).
77 Correlations and associations between antibody response and other variables were examined using
78 Spearman's rank-based correlation coefficients, rank-sum test, and χ^2 -squared tests. R^2 -statistics were

79 obtained from multiple linear regression models with antibody response as the dependent variable. The
80 optimal cut-off to separate patients with and without vaccination response was assessed by employing
81 a maximized Youden's index within a receiver operating characteristic (ROC) analysis. Logistic
82 models were used for univariate and multivariate modeling of the vaccination response. The Kruskal–
83 Wallis test was used for continuous variables when comparing three or more treatment groups. The
84 Kruskal–Wallis H test was used as a post-hoc test to determine between-group differences.

85

86 RESULTS

87 Study population

88 Complete data of 199 study participants who completed their full vaccination schedule were included
89 in the efficacy analysis. Of these, 79 were healthy participants and 120 were immunocompromised
90 patients. All study participants were vaccinated with mRNA-1273, with only two healthy individuals
91 (1%) receiving BNT162b2. A total of 140 adverse events occurred after vaccination, with the most
92 common being pain at the injection site, headache, fever, and fatigue. Four severe adverse events
93 (hospitalization and death due to HM and bone fractures) were considered unrelated to vaccination.
94 Participant characteristics are detailed in Table 1. Diagnoses, immunosuppressive treatments, and
95 antibody responses for subgroups are listed in Supplementary Table 1.

96 **Table 1. Baseline characteristics of the study population and rate of vaccination response.**

Variable	Overall (n=199)	Healthy (n=79)	Immunocompromised (n=120)	P
Age (years)	54 [43-62]	51 [36-56]	58 [50-65]	<0.001
Female gender	110 (55)	45 (57)	65 (54)	0.698
Body mass index (kg/m ²)	24.4 [22.2-27.0]	23.7 [21.6-26.4]	24.8 [22.7-27.8]	0.039
Immunodeficiency group				n/a
Primary immunodeficiency			25 (21)	
Autoimmune disease			39 (32)	
Haematologic disease			56 (47)	
Vaccine				0.080

mRNA-1273 (Moderna)	197 (99)	77 (97)	120 (100)	
BNT162b2 (BioNTech/Pfizer)	2 (1)	2 (3)	0 (0)	
B-cell depleting therapy				n/a
None	123 (62)		44 (37)	
Rituximab	35 (18)		35 (29)	
Ocrelizumab	6 (3)		6 (5)	
HSCT	35 (17)		35 (29)	
Days since depletion			166 [69-545]	
Antibody Response				
Roche any response	159 (80)	79 (100)	80 (67)	<0.001
Roche stringent response	117 (59)	79 (100)	38 (32)	<0.001
Roche U/mL	2020 [4-2500]	2500 [2500-2500]	67 [0-1947]	<0.001
DiaSorin any response	177 (89)	79 (100)	98 (82)	<0.001
DiaSorin stringent response	105 (53)	79 (100)	26 (22)	<0.001
DiaSorin BAU/mL	2080 [142-2080]	2080 [2080-2080]	233 [12-1760]	<0.001

97 Data are reported as medians [25th-75th percentile] and absolute frequencies (%). P-values are from
 98 rank-sum tests, χ^2 -tests, and Fisher's exact tests, as appropriate. Significant P-values are highlighted in
 99 bold type. Any response, any seroconversion; BAU, binding antibody unit; DiaSorin stringent
 100 response, DiaSorin SARS-CoV-2 TrimericS IgG ≥ 2000 BAU/mL; HSCT, haematopoietic stem cell
 101 transplantation; Roche stringent response, Roche anti-SARS-CoV-2 S total antibody titre ≥ 1000
 102 U/mL.

103

104 Immunogenicity of mRNA vaccines

105 Antibody responses were assessed using two different assays. All healthy controls demonstrated
 106 seroconversion with high antibody titers (Roche median: 2500 U/mL; DiaSorin median: 2080
 107 BAU/mL). In immunocompromised patients, the seroconversion rates and antibody levels were
 108 significantly lower than those in healthy controls (Table 1 and Figure 1); 67% (n = 80) and 82% (n =
 109 98) of patients demonstrated a humoral response with antibody levels within the quantification range
 110 of Roche and DiaSorin assays, respectively. Since the clinical significance of antibody levels close to
 111 the limit of detection was unclear, we defined more stringent thresholds. In our patients, we defined a
 112 "stringent response" as reaching at least the lowest antibody level of the healthy individuals from our

113 cohort (Roche ≥ 1000 U/mL; DiaSorin ≥ 2000 BAU/mL). According to this definition, only 32%
114 (Roche) and 22% (DiaSorin) of patients had a stringent antibody response. This difference was not
115 statistically significant between the two tests ($P = 0.108$). Patients who received anti-CD20 therapy,
116 including the majority of patients with AIRD, had the lowest rate of stringent response ($\leq 10\%$).
117 Interestingly, patients who received HSCT demonstrated a relatively high rate of stringent response
118 [37% (13/35)]. There was no statistically significant difference between allogeneic and autologous
119 HSCT (40% vs. 30%, respectively; $P = 0.541$). The antibody levels of both assays showed an excellent
120 correlation with each other ($P = 0.915$, $P < 0.001$, $R^2 = 0.841$; Table 2; Figure 2A). Since the Roche
121 assay is more widely used in research and shows a good correlation with live virus neutralization tests
122 in vaccinated individuals,[15, 20, 24, 26] we focused on the Roche assay for subsequent analyses to
123 ensure comparability with other studies.

124 **Correlation of antibody levels with the amount of B-cell subsets**

125 The total number of B cells and all B-cell subsets were positively correlated with the antibody levels in
126 all patients (Roche: $P = 0.739$, $R^2 = 0.001$, $P < 0.001$; Table 2; Figure 2B). In this analysis, the absolute
127 number of naïve B cells showed the highest correlation with antibody titers (Roche: $P = 0.761$, $R^2 =$
128 0.153 ; Figure 2C). Furthermore, this analysis also indicated that the time between the last B-cell-
129 depleting therapy and vaccination was also a significant factor correlating with antibody levels.
130 Extending this correlation analysis to the entire study population (Supplementary Table 2;
131 Supplementary Figure 2), the influence of naïve B cells remained highly significant (Roche: $P = 0.636$,
132 $P < 0.001$, $R^2 = 0.123$). However, because the age of healthy subjects was significantly lower than that
133 of patients, age appeared to be a significant factor negatively correlated with anti-SARS-CoV-2
134 antibodies after vaccination in the entire study population (Roche: $p = -0.209$, $R^2 = 0.057$).

135 **Table 2. Correlations of SARS-CoV-2 antibody assays with different variables in the**
136 **immunocompromised study population.**

Variable	Roche anti-SARS-CoV-2			DiaSorin anti-SARS-CoV-2		
	ρ	P	R^2	ρ	P	R^2
Roche anti-SARS-CoV-2 S				0.915	<0.001	0.841
DiaSorin SARS-CoV-2	0.915	<0.001	0.841			

TrimericS IgG						
Age	0.091	0.321	0.001	0.086	0.349	0.005
Body mass index	0.169	0.076	0.004	0.160	0.093	0.005
Days since last B-cell depletion	0.595	<0.001	0.041	0.479	<0.001	0.063
Interval in days from last B-cell depleting therapy to vaccination up to 365 days	0.481	0.001	0.096	0.422	0.002	0.095
IgA	0.042	0.651	0.015	0.178	0.052	0.025
IgG	0.065	0.481	0.031	0.124	0.179	0.023
IgM	0.386	<0.001	0.002	0.424	<0.001	0.002
Lymphocytes abs.	0.222	0.018	0.002	0.177	0.059	0.001
T cells abs.	0.112	0.236	0.034	0.099	0.293	0.029
Cytotoxic T cells abs.	0.170	0.071	0.005	0.157	0.095	0.008
T helper cells abs.	0.025	0.789	0.062	0.037	0.693	0.045
NK cells abs.	-0.014	0.880	0.014	0.008	0.929	0.003
B cells abs.	0.739	<0.001	0.001	0.631	<0.001	0.001
CD45 ⁺ cells abs.	0.227	0.015	0.002	0.192	0.041	0.001
Transitional B cells abs.	0.491	<0.001	0.033	0.393	<0.001	0.029
Naïve B cells abs.	0.761	<0.001	0.153	0.661	<0.001	0.132
Pre-switch memory B cells abs.	0.657	<0.001	0.004	0.572	<0.001	0.004
Switched memory B cells abs.	0.710	<0.001	0.003	0.065	<0.001	0.005
CD21 ⁻ B cells abs.	0.640	<0.001	0.001	0.554	<0.001	0.001
Plasmablasts abs.	0.580	<0.001	0.001	0.523	<0.001	0.008

137 Correlations were computed with Spearman's rank-based rho adjusted for multiple testing (n=21) with
 138 Šidák correction. The Šidák-adjusted α level is approximately 0.00244. Significant P-values are
 139 highlighted in bold type. Abs., absolute count.

140

141 To support the results of our correlation analyses, we established a model of stringent vaccination
 142 response prediction for the entire study population based on the results of the Roche assay using the
 143 area under the ROC curve (AUC; Supplementary Table 3). This model suggests that the total number
 144 of B cells (AUC: 0.87, 95% CI: 0.79–0.92), naïve B cells (AUC: 0.82, 95% CI: 0.73–0.88), pre-switch
 145 memory B cells (AUC: 0.84, 95% CI: 0.76–0.89), and switched memory B cells (AUC: 0.85, 95% CI:
 146 0.79–0.91) can best describe the response to vaccination in the entire study population, and that age
 147 does not play a significant role.

148 **Naïve B cells show the strongest association with stringent**
149 **response**

150 To test the association of variables with vaccination response determined by the Roche assay, we
151 performed univariate and multivariate linear regression analyses on the entire study population using
152 the same variables from the correlation analyses.

153 In univariate analysis (Table 3), the variables found to be significantly associated with any antibody
154 response in patients included interval in days from the last B-cell-depleting therapy, naïve B-cell
155 count, pre-switch memory B-cell count, and absolute number of plasmablasts. The same correlation
156 was also found for stringent antibody responses, except for the correlation with pre-switch memory
157 B cells. The absolute number of these B-cell subsets was significantly lower in patients than in healthy
158 controls, in patients after monoclonal anti-CD20 antibody therapy compared to HSCT, and in patients
159 without seroconversion compared to those with any antibody response (not shown) or stringent
160 response (Supplementary Figure 3). The variables of immunodeficient patients stratified by
161 vaccination response are shown in Supplementary Table 4. In the univariate analysis of the entire
162 cohort (Supplementary Table 5), the same B-cell subsets remained significantly associated with
163 vaccine response. In addition, we found a negative correlation with age, but only for the stringent
164 antibody response [odds ratio (OR): 0.69 per 10-year increase, 95% CI: 0.54–0.87, P = 0.001].

165 **Table 3. Univariate linear regression analysis to test the association of variables with**
166 **vaccination response determined by the Roche anti-SARS-CoV-2 S assay in the immunodeficient**
167 **cohort.**

Variable	Any Response			Stringent Response		
	OR	95% CI	P	OR	95% CI	P
Age (per 10 years)	1.23	0.92-1.66	0.167	1.02	0.76-1.38	0.880
Body mass index (per 5 point)	1.20	0.77-1.87	0.420	1.11	0.71-1.38	0.633
Interval in days from last B-cell depleting therapy to vaccination up to 365 days (per 30 days)*	1.41	1.13-1.76	0.002	1.31	1.02-1.67	0.035
IgA (per 1g/L)	0.74	0.50-	0.136	1.30	0.87-	0.199

		1.10			1.93	
IgG (per 5g/L)	0.96	0.62-1.49	0.848	1.43	0.90-2.27	0.127
IgM (per 1g/L)	1.32	0.83-2.10	0.246	0.98	0.92-1.05	0.677
Lymphocytes abs. (per 1 G/L)	0.94	0.81-1.10	0.461	1.03	0.89-1.18	0.686
T cells abs. (per 10/ μ L)	1.00	0.99-1.01	0.693	1.00	0.99-1.01	0.101
Cytotoxic T cells abs. (per 10/ μ L)	1.01	0.99-1.02	0.143	1.00	0.99-1.01	0.846
T helper cells abs. (per 10/ μ L)	0.99	0.98-1.01	0.403	1.01	1.00-1.02	0.009
NK cells abs. (per 10/ μ L)	0.98	0.96-1.01	0.139	1.01	0.99-1.03	0.180
B cells abs. (per 10/ μ L)	0.99	0.99-1.01	0.401	0.99	0.99-1.01	0.931
CD45 ⁺ cells abs. (per 10/ μ L)	0.99	0.99-1.01	0.045	1.00	0.99-1.01	0.653
Transitional B cells abs. (per 1/ μ L)	1.17	0.97-1.42	0.094	1.05	0.96-1.15	0.233
Naïve B cells abs. (per 10/ μ L)	1.17	1.07-1.28	0.001	1.09	1.04-1.14	<0.001
Pre-switch memory B cells abs. (per 10/ μ L)	1.78	1.09-2.92	0.021	1.03	0.95-1.11	0.480
Switched memory B cells abs. (per 10/ μ L)	0.99	0.99-1.01	0.406	0.99	0.99-1.00	0.957
CD21 ⁻ B cells abs. (per 10/ μ L)	0.99	0.98-1.01	0.512	1.00	0.99-1.01	0.746
Plasmablasts abs. (per 1/ μ L)	7.95	2.68-23.4	<0.001	1.85	1.24-2.74	0.002

168 Significant P-values are highlighted in bold type. Any response, any seroconversion; OR, odds ratio;
 169 stringent response, total antibody titre \geq 1000 U/mL. Abs., absolute count.

170

171 In multivariable analysis for stringent response, only the number of naïve B cells was an independent
 172 predictor (OR: 1.07 per 10- μ L increase, 95% CI: 1.02–1.12, P = 0.009). The only independent
 173 predictor of any seroconversion was plasmablast count (OR: 4.42 per 1- μ L increase, 95% CI: 1.30–
 174 15.01, P = 0.017). The interval since the last B-cell-depleting therapy had to be excluded because this
 175 variable was not applicable to all patients.

176 The multivariable analyses for the entire study population are shown in Supplementary Tables 6 and 7.

177 The absolute number of naïve B cells remained an independent predictor of stringent antibody

178 response (OR: 1.14 per 10- μ L increase, 95% CI: 1.08–1.20, $P < 0.001$), while age was not associated
179 with vaccination response.

180 **Exploratory analyses**

181 As naïve B cells were the only B-cell subset independently associated with stringent antibody
182 response, we were interested to determine whether our dataset allowed us to estimate a naïve B cell
183 count threshold for stringent antibody response. ROC analysis and non-linear risk modeling predicted
184 that at least six or more naïve B cells per μ L were required to generate a stringent vaccine response
185 (Figures 3A, B).

186 A second exploratory ROC analysis was undertaken to determine the minimum interval between the
187 last B-cell-depleting therapy, i.e., anti-CD20 antibody therapy or HSCT up to 365 days ($n = 53$), and
188 vaccination differentiating any seroconversion versus no vaccination response. The optimal cut-off in
189 this population was 116 days or more (Figure 3C).

190

191 **DISCUSSION**

192 We investigated the relationship between B-cell subsets and humoral vaccination response to
193 COVID-19 mRNA vaccination in immunocompromised patients and healthy controls. Recent
194 publications show diverging antibody levels depending on the underlying diseases of the investigated
195 population, age, and immunosuppressive treatments. Our findings confirm those from recent literature,
196 which demonstrated that immunocompromised individuals show significantly lower and more
197 heterogeneous antibody titers than healthy controls.[10, 11, 15, 17-21, 24]

198 In one of the largest studies published on COVID-19 vaccination in patients with HM, Maneikis et al.
199 reported lower median anti-S1 IgG responses after two BNT162b2 vaccine doses in 653 patients with
200 HM than 69 healthy healthcare workers.[16] However, the response was highly heterogeneous, with
201 many patients reaching an antibody response similar to that of healthy controls. Even in the group
202 treated with anti-CD20 therapy, 19% had anti-S1 IgG antibodies in the range of healthy controls.

203 While the factors responsible for such a favorable humoral vaccination response are unknown, a
204 similar heterogeneity in vaccination response has been reported for PID,[10] AIRD,[12] and
205 anti-CD20 therapy in several studies.[15, 16, 20, 27] Recently, Mrak et al. found that the presence of
206 circulating B cells was essential for the humoral response to BNT162b2 after rituximab therapy.[24]
207 While they found a moderate correlation with the relative abundance of circulating B cells, they state
208 that the mere presence of peripheral B cells allows seroconversion irrespective of the B cell count.[24]
209 Interestingly, in our univariate analysis, the absolute number of CD19⁺ B cells prior to vaccination was
210 not associated with anti-SARS-CoV-2 response in patients, whereas naïve B cells, pre-switch memory
211 B cells, and plasmablasts were associated with seroconversion. However, only naïve B cells were
212 independent predictors of stringent vaccination responses (i.e., similar to healthy subjects) in the
213 multivariable analysis.

214 The abundance of circulating naïve B cells predicted stringent vaccination responses in patients across
215 a wide range of diseases and treatments, suggesting the functional importance of these cells in the
216 humoral immune response. Indeed, the production of specific antibodies to a novel antigen relies on
217 the presence of antigen-specific B cells within the naïve B cell pool.[28] Thus, a drastically contracted
218 pool of naïve B cells reduces the chance of harboring B cells with a B-cell receptor of high avidity to
219 the antigen. Only B cells with a high B-cell receptor/antigen avidity can interact with T follicular
220 helper cells successfully and subsequently undergo somatic hypermutation to develop an optimal
221 antibody response.[29] A lack of these cells results in low antibody titers of poor quality. Therefore,
222 the association of the humoral vaccination response with the abundance of naïve B cells is most likely
223 a causal relationship.

224 Establishment of protective humoral immunity following vaccination may be impaired until the naïve
225 B cells repopulate.[5] Therefore, current recommendations suggest time intervals of up to six months
226 between the most recent rituximab administration and vaccination.[30-32] Our data confirm that time
227 intervals play a role in seroconversion, with an estimated cut-off of 116 days from the last B-cell-
228 depleting therapy and vaccination. Nevertheless, several independent statistical models suggest that
229 B-cell subsets, the targets of these therapies, are the actual predictors of vaccination response. In a

230 larger cohort, Mrak et al. found that the time since the last rituximab treatment correlated with B-cell
231 frequency but was not an independent predictor of seroconversion.[24]

232 Our study had several limitations. These include single-center design and limited representation of
233 some patient cohorts that do not allow clear conclusions on seroconversion rates among less common
234 entities or less frequently used treatment strategies. Moreover, we cannot make any statements about
235 the persistence of the vaccination response at this point. Our study relies on the measurement of
236 antibodies as a surrogate for immunity to COVID-19. However, our results do not significantly differ
237 between the two internationally deployed anti-spike protein serological assays for detecting either total
238 IgG or IgG. Both tests showed a high correlation with surrogate neutralization tests, and Roche's assay
239 correlated well with live virus neutralization tests in vaccinated individuals.[24, 26] The strength of
240 our study is its prospective design and the introduction of the stringent vaccination response as a
241 potentially more relevant concept than seroconversion.

242 In summary, the humoral response to the SARS-CoV-2 mRNA vaccine is impaired in
243 immunocompromised patients. The abundance of circulating naïve B cells is strongly associated with
244 a normal antibody vaccine response across different conditions and therapies. Therefore, measuring
245 naïve B cells may predict the humoral response to COVID-19 vaccination. Further research is needed
246 to confirm these findings vaccinating immunocompromised individuals against COVID-19 and other
247 pathogens.

248

249 **Acknowledgments**

250 We thank Pia-Carina Gallaun and Julia Lodron for technical assistance. The samples/data used for this
251 project were processed with the help of the Biobank Graz of the Medical University of Graz, Austria.

252 **Author contributions**

253 IH, ES, PS, SH, HG, IS, and MHS designed the study. ES, IH, PF, NS, JF, BD, BU, AG, MM, CU,
254 MK, CE and BK collected clinical samples and/or data. PF and BK performed antibody assays. ES
255 and SH analyzed the data and performed the statistical analysis. ES, SH, IH, PS, HG, IS, and MHS

256 critically reviewed and discussed the results. ES, IH, PF, HS, HG, and MHS wrote the first draft. All
257 authors reviewed the draft and approved the final version of the manuscript.

258 **Competing interests**

259 None of the contributing authors have a conflict of interest, including specific financial interests,
260 relationships, and affiliations relevant to the topic or materials covered in the manuscript.

261 **Funding**

262 None

263

264 **REFERENCES**

- 265 1 Shields AM, Burns SO, Savic S, et al. COVID-19 in patients with primary and secondary
266 immunodeficiency: The United Kingdom experience, *J Allergy Clin Immunol* 2021;147:870,875.e1.
- 267 2 Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer
268 (CCC19): a cohort study, *Lancet* 2020;395:1907-18.
- 269 3 Hatzl S, Eisner F, Schilcher G, et al. Response to "COVID-19 in persons with haematological
270 cancers", *Leukemia* 2020;34:2265-70.
- 271 4 Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and
272 COVID-19: a systematic review and meta-analysis of 3377 patients, *Blood* 2020;136:2881-92.
- 273 5 Baker D, Roberts CAK, Pryce G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting
274 therapy in autoimmune diseases, *Clin Exp Immunol* 2020;202:149-61.
- 275 6 Ribas A, Sengupta R, Locke T, et al. Priority COVID-19 Vaccination for Patients with Cancer while
276 Vaccine Supply Is Limited, *Cancer Discov* 2021;11:233-6.
- 277 7 van der Veldt, A A M, Oosting SF, Dingemans AC, et al. COVID-19 vaccination: the VOICE for
278 patients with cancer, *Nat Med* 2021;27:568-9.
- 279 8 Ameratunga R, Longhurst H, Steele R, et al. Common Variable Immunodeficiency Disorders, T-Cell
280 Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19, *J Allergy Clin Immunol*
281 *Pract* 2021.
- 282 9 Furer V, Rondaan C, Agmon-Levin N, et al. Point of view on the vaccination against COVID-19 in
283 patients with autoimmune inflammatory rheumatic diseases, *RMD Open* 2021;7:e001594. doi:
284 10.1136/rmdopen-2021.
- 285 10 Hagin D, Freund T, Navon M, et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in
286 patients with inborn errors of immunity, *J Allergy Clin Immunol* 2021.

- 287 11 Braun-Moscovici Y, Kaplan M, Braun M, et al. Disease activity and humoral response in patients
288 with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-
289 CoV-2, *Ann Rheum Dis* 2021.
- 290 12 Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-
291 19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general
292 population: a multicentre study, *Ann Rheum Dis* 2021.
- 293 13 Deepak P, Kim W, Paley MA, et al. Glucocorticoids and B Cell Depleting Agents Substantially
294 Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2, *medRxiv* 2021.
- 295 14 Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion rates following COVID-19
296 vaccination among patients with cancer, *Cancer Cell* 2021.
- 297 15 Greenberger LM, Saltzman LA, Senefeld JW, et al. Antibody response to SARS-CoV-2 vaccines in
298 patients with hematologic malignancies, *Cancer Cell* 2021 doi:10.1016/j.ccell.2021.07.012.
- 299 16 Maneikis K, Šablauskas K, Ringelevičiūtė U, et al. Immunogenicity of the BNT162b2 COVID-19
300 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania:
301 a national prospective cohort study, *Lancet Haematol* 2021;8:e583-92.
- 302 17 Avivi I, Balaban R, Shragai T, et al. Humoral response rate and predictors of response to
303 BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma, *Br J Haematol* 2021.
- 304 18 Bird S, Panopoulou A, Shea RL, et al. Response to first vaccination against SARS-CoV-2 in
305 patients with multiple myeloma, *Lancet Haematol* 2021;8:e389-92.
- 306 19 Gavriatopoulou M, Terpos E, Kastritis E, et al. Low neutralizing antibody responses in WM, CLL
307 and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine, *Clin Exp Med* 2021:1-
308 5.
- 309 20 Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in
310 patients with chronic lymphocytic leukemia, *Blood* 2021;137:3165-73.
- 311 21 Pimpinelli F, Marchesi F, Piaggio G, et al. Fifth-week immunogenicity and safety of anti-SARS-
312 CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on
313 active treatment: preliminary data from a single institution, *J Hematol Oncol* 2021;14:81-021.
- 314 22 Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of
315 the immunocompromised host, *Clin Infect Dis* 2014;58:e44-100.
- 316 23 Jaffe D, Papadopoulos EB, Young JW, et al. Immunogenicity of recombinant hepatitis B vaccine
317 (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants, *Blood*
318 2006;108:2470-5.
- 319 24 Mrak D, Tobudic S, Koblichke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B
320 cells promote humoral immune responses in the presence of T-cell-mediated immunity, *Ann Rheum*
321 *Dis* 2021.
- 322 25 Stradner MH, Dejaco C, Brickmann K, et al. A combination of cellular biomarkers predicts failure
323 to respond to rituximab in rheumatoid arthritis: a 24-week observational study, *Arthritis Res Ther*
324 2016;18:190-016.

- 325 26 Perkmann T, Perkmann-Nagele N, Koller T, et al. Anti-Spike Protein Assays to Determine SARS-
326 CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays, *Microbiol Spectr*
327 2021:e0024721.
- 328 27 Herzog Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID-19 vaccine is significantly less
329 effective in patients with hematologic malignancies, *Am J Hematol* 2021.
- 330 28 Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age, *Nat Rev Immunol*
331 2009;9:185-94.
- 332 29 Chan TD, Brink R. Affinity-based selection and the germinal center response, *Immunol Rev*
333 2012;247:11-23.
- 334 30 Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination
335 in adult patients with autoimmune inflammatory rheumatic diseases, *Ann Rheum Dis* 2020;79:39-52.
- 336 31 Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for
337 COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2,
338 *Arthritis Rheumatol* 2021;73:e30-45.
- 339 32 Arnold J, Winthrop K, Emery P. COVID-19 vaccination and antirheumatic therapy, *Rheumatology*
340 (*Oxford*) 2021.

341

342 **FIGURE LEGENDS**

343 **Figure 1.** Immune response to SARS-CoV-2 mRNA vaccination. The scatter plot shows total Ig
344 levels for healthy controls, immunodeficient patients and patients after anti-CD20 therapy or
345 haematopoietic stem cell transplantation (HSCT). P is <0.001 between all groups calculated with the
346 Kruskal-Wallis test and post hoc analysis. Lines are medians with interquartile range. The Plot was
347 drawn with GraphPad Prism Version 9.2.0.332.

348 **Figure 2.** Correlation of antibody levels determined by Roche anti-SARS-CoV-2 S assay with
349 B cells in patients. (A.) DiaSorin SARS-CoV-2 TrimericS IgG. (B.) Absolute number of B cells
350 (CD19⁺ cells). (C.) Absolute number of naïve B cells. Scatter plots indicate a linear regression line
351 including a 95% confidence interval. In case of A. and B., regression line corresponds to transformed
352 data using $x=\log((x+1))$ and $y=\log((y+1))$, respectively.

353 **Figure 3.** Exploratory analyses estimating the number of naïve B cells and the interval to the
354 last B-cell depleting therapy required for a vaccination response. (A.) The receiver operating
355 characteristic (ROC) analysis curve for naïve B cells differentiating stringent antibody response vs no
356 or any vaccination response in the whole study population (n=189) shows excellent discrimination.
357 (B.) A non-linear risk model based on the observed risk of seroconversion was created to estimate the
358 minimum number of naïve B cells required for a stringent vaccination response. Independently, the
359 best discriminatory cut-off (dashed line) was determined with the Youden's index from the ROC
360 curve. Both models predict that six or more naïve B cell per μL are required to generate a stringent
361 vaccine response. (C.) The ROC analysis curve for the interval since the last B-cell depleting therapy
362 up to 365 days (n=53) differentiating any seroconversion vs no vaccination response. The optimal cut-
363 off is an interval of 116 days or more.

364

Roche anti-SARS-CoV-2 S total Ig [U/mL]




Figure 2






Figure 3

A



B



C

